Bacterial conjunctivitis is a common type of pink eye, caused by bacteria that infect the eye through various sources of contamination. The bacteria can be spread through contact with an infected individual, exposure to contaminated surfaces or through other means such as sinus or ear infections. Several common medications are used to treat or reduce the symptoms of bacterial conjunctivitis. The mainstay of treatment for bacterial conjunctivitis is topical antibiotic therapy, with the intent of significantly reducing the duration of symptoms and likelihood of contagion. Bacterial conjunctivitis is a commonly encountered eye problem across the world, caused by various bacterial strains such as streptococci, staphylococci, chlamydial, and gonococci organisms. Majority of the cases of bacterial conjunctivitis are self-limited and acute and not a major cause of morbidity.
The global bacterial conjunctivitis drugs market report provides market size (Revenue USD Million 2014 to 2021), market share, market trends and forecasts growth trends (CAGR%, 2017 to 2021).
The global bacterial conjunctivitis drugs market segmentation is based on drug class (fluoroquinolones, ciprofloxacin, ofloxacin, levofloxacin, moxifloxacin, gatifloxacin, besifloxacin, aminoglycosides, tobramycin, gentamicin, macrolides, erythromycin, azithromycin, bacitracin, doxycycline, polymyxine and fusidic acid).
The global bacterial conjunctivitis drugs market report also provides the detailed market landscape (market drivers, restraints, opportunities), market attractiveness analysis and profiles of major competitors in the global market including company overview, financial snapshot, key products, technologies and services offered, and recent developments. The global bacterial conjunctivitis drugs market research report is divided by geography (regional and country based) into North America (U.S., Canada), Latin America (Brazil, Mexico, Rest of LA), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of APAC), and Rest of the World.
Major players operating in the global bacterial conjunctivitis drugs market and included in this report are Actavis plc, Akorn, Inc., Bayer AG, F. Hoffmann-La Roche, Ltd., Merck & Co., Inc., Novartis AG, Perrigo Company plc, Pfizer, Inc., Santen Pharmaceutical Co. Ltd., and Valeant Pharmaceuticals International, Inc.